bioAffinity Technologies Inc. stocks have been trading up by 16.23 percent following highly positive news driving strong investor optimism
Click Here for a Millionaire's POV on Trading BIAF
SUBSCRIBE FOR ALERTSJOIN 50,000+ ACTIVE TRADERS
Key Takeaways
- Hong Kong patent win for CyPath Lung strengthens bioAffinity Technologies’ IP in Asia, building on an earlier China patent and supporting its lab-developed noninvasive lung cancer test.
- Patent news for bioAffinity Technologies’ lung-cancer prediction platform sent BIAF up about 59% on a huge volume spike, showcasing how headline-sensitive this micro-cap name is.
- Nasdaq compliance has been restored for BIAF common stock and warrants, removing immediate delisting risk and letting management refocus on commercialization.
- The company is pushing CyPath Lung beyond early detection into post-treatment surveillance of lung cancer survivors, aiming to complement imaging in recurrence monitoring.
- Management plans a corporate update and one-on-one meetings at the H.C. Wainwright Global Investment Conference, spotlighting milestones and platform expansion.
Live Update At 09:17:41 EDT: On Friday, September 18, 2026 bioAffinity Technologies Inc. stock [NASDAQ: BIAF] is trending up by 16.23%! Discover the key drivers behind this movement as well as our expert analysis in the detailed breakdown below.
Quick Financial Overview
BIAF is trading like a classic small-cap biotech momentum play. In the last few weeks, bioAffinity Technologies ran from a close of $4.56 on 2026/08/31 to a high near $20.35 on 2026/09/04, before pulling back and recently closing around $8.75 on 2026/09/17. That is a huge round-trip, and it tells traders this tape rewards speed and punishes hesitation.
Intraday, BIAF’s 5‑minute chart shows heavy back-and-forth between roughly $8.50 and $10.50, with repeated pushes over $10 fading. That intraday action signals active day trading, fast profit-taking, and little patience for chasing. The stock tends to spike on headlines, then grind lower when volume cools.
More Breaking News
- GOOGL Stock Draws Bullish Targets As AI Bets Scale Up
- GGB Stock Slips As Wall Street Turns Cautious On Steel Margins
- CPOP Stock Spikes On Heavy Volume As Traders Hunt Volatility
- EQPT Stock Falls As EquipmentShare.com Faces Securities Class Actions
Fundamentally, bioAffinity Technologies is still deep in the red. Quarterly revenue is about $1.51M, but net loss is roughly $3.37M, producing brutal negative margins and ugly return-on-equity metrics. Cash at period end sits near $2.43M, and recent cash flow shows operating burn above $3.2M, partly funded by stock issuance. For traders, that means dilution risk stays on the radar even as BIAF builds its lung cancer diagnostics franchise.
Why Traders Are Watching BIAF Right Now
The latest spark in BIAF came from real news, not chat room hype. bioAffinity Technologies secured a Hong Kong patent for its CyPath Lung platform, adding to an earlier China patent and rounding out a stronger IP wall across Asia. That IP win matters because CyPath Lung is already on the market as a lab-developed, noninvasive sputum test for lung cancer detection with solid clinical performance. The market reacted fast: one report tied the Hong Kong patent headline to an approximately 59% surge in BIAF on massive volume.
For momentum traders, that move confirms BIAF as a headline-driven ticker. When bioAffinity Technologies drops material updates — especially around patents, clinical uses, or commercialization — the stock can move multiple points in minutes. The Hong Kong patent also feeds a bigger story: Asia is a huge potential market for lung cancer diagnostics, and real patent coverage is often a precondition for serious partnerships or licensing talks. Traders don’t need those deals in hand today; they just need the story to stay alive.
At the same time, BIAF quietly removed a big overhang. bioAffinity Technologies regained compliance with Nasdaq listing standards for both its common stock and BIAFW warrants. That takes near-term delisting risk off the table and stabilizes the trading venue. Combine that with the company’s push to move CyPath Lung beyond early detection into post-treatment surveillance of lung cancer survivors, and you get a platform that is expanding, not shrinking. Add an upcoming corporate update and one-on-one meetings at the H.C. Wainwright conference, and BIAF now has a clear pipeline of potential catalysts that active traders will track on the calendar.
Conclusion
BIAF sits at the crossroads of story and structure. On the story side, bioAffinity Technologies now owns both China and Hong Kong patents around its CyPath Lung technology, is targeting not just early detection but also surveillance of lung cancer survivors, and is building commercial experience with a real, marketed lab-developed test. Those pieces give traders a concrete theme: noninvasive lung cancer diagnostics attacking a large global market, with Asia moving into focus.
On the structure side, the tape is wild. BIAF has shown it can spike 50%+ on a single patent headline, then retrace hard as day traders exit. Financials show revenue growth but heavy losses, cash burn, and reliance on equity funding — classic small-cap biotech traits. Restored Nasdaq compliance lowers one key risk, yet does not erase the possibility of future capital raises as bioAffinity Technologies scales.
For traders in the Tim Sykes and Tim Bohen community, this is exactly the kind of name that demands discipline. As Tim Sykes likes to remind students, “Volatility is an opportunity, not a guarantee — the edge comes from meticulous planning and cutting losses quickly when the trade proves you wrong.” As Tim Bohen, lead trainer with StocksToTrade says, “I focus on momentum that’s visible right now. Speculation on future moves is outside my playbook.” BIAF offers volatility, a real news pipeline, and a clear story; the rest comes down to your preparation, risk management, and ability to avoid chasing when the crowd loses its head.
This is stock news, not investment advice. StocksToTrade News delivers real-time stock market updates tailored to highlight the key catalysts driving short-term price movements. Our coverage is designed for active traders and investors who thrive in fast-moving markets, with a focus on volatile sectors like penny stocks, AI stocks, Robinhood stocks and other momentum plays. From earnings reports and FDA approvals to mergers, new contracts, and unusual trading volume, we break down the events that can spark significant price action.
Looking to level up your trading game? Explore StocksToTrade, the ultimate platform for traders. With powerful tools designed for swing and day trading, integrated news scanning, and even social media monitoring, StocksToTrade keeps you one step ahead.
Check out our quick startup guide for new traders!
- How to Read Stock Charts: A Guide for Beginners
- Trading Plan: 6 Steps to Create One
- How To Create a Stock Watchlist
Ready to build your watchlists? Check out these curated lists:
Once your watchlist is set, take the next step and trade with confidence using StocksToTrade’s robust platform. Don’t miss out — grab your 14-day trial for just $7 and experience the edge you need to thrive in today’s fast-paced markets.